Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Rapid Communications

Rapid Communications 4: Reproductive and Developmental Endocrinology

ea0090rc4.1 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Sars-CoV-2 infection leads to significant and long-lasting changes in women’s reproductive health

Saravinovska Kristina , Marina Ljiljana , Petkovic Dunja-Simona , Delic Neda , Sojat Antoan Stefan , Petkovic Tijana , Antic Natalija , Mihajlovic Sladjana , Lackovic Milan , Radonjic Nevena , Ivovic Miomira , Arizanovic Zorana , Vujovic Svetlana

Background: Reproductive health is a state of complete physical, mental, and social well-being. So far, there is limited evidence about the consequences of Sars-CoV-2 infection on women’s reproductive health.Aim: To determine the effects of Sars-CoV-2 infection on women’s reproductive health.Methods: We created an anonymous survey about reproductive health and shared it with women of reproductive age between May 2022 and ...

ea0090rc4.2 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Evolution of cardiovascular risk markers in polycystic ovary syndrome: Results from a long-term monocentric cohort study

Cecchetti Carolina , Pandurevic Srdjan , Dionese Paola , Belardinelli Elisabetta , Rotolo Laura , Fanelli Flaminia , Bergamaschi Luca , Pizzi Carmine , Pagotto Uberto , Gambineri Alessandra

Background: Many questions concerning polycystic ovary syndrome (PCOS) remain unsolved, such as the long term evolution of cardiovascular (CV) risk markers and the risk for CV events.Methods: A total of 119 PCOS patients diagnosed in 2009 by NIH criteria at our Unit were evaluated at baseline for cardiovascular risk markers (hypertension, diabetes mellitus-DM, dyslipidaemia, obesity, carotid intima media thickness-cIMT, and epicardial fat thickness-EFT) ...

ea0090rc4.3 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Body composition and metabolic characteristics in different PCOS phenotypes

Opalic Milica , Ognjanovic Sanja , Popovic Bojana , Ilic Dusan , Bjekic-Macut Jelica , Kovacevic Valentina Elezovic , Radic Lena , Livadas Sarantis , Mastorakos George , Macut Djuro P.

Introduction: Polycystic ovary syndrome (PCOS) is the most prevalent endocrinopathy among women during reproductive age. Using ESHRE/ASRM diagnosis of PCOS is considered when 2 of 3 criteria are present: polycystic ovary morphology (PCOM), oligo/anovulation (ANOV) and hyperandrogenism (HA). These criteria form four different phenotypes: A (ANOV, HA, PCOM), B (ANOV, HA), C (HA, PCOM) and D (ANOV, PCOM). Several studies have found differences in anthropometric, hormonal and meta...

ea0090rc4.4 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Is AMH a regulator of autophagy in the ovary?

Tatiana Lecot-Connan , Yasmine Boumerdassi , Francoise Magnin , Nadine Binart , Charlotte Sonigo , Beau Isabelle

Background: The reserve pool of primordial follicles (PMF) is finely regulated by molecules implicated in follicular growth or PMF survival. Anti-Müllerian Hormone (AMH), produced by granulosa cells of growing follicles, is known for its inhibitory role in the initiation of PMF growth. We observed in a recent in vivo study that injection of AMH into mice seemed to induce an activation of autophagy, a cytoplasmic lysosomal-dependent degradation system, which is im...

ea0090rc4.5 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Women carrying CYP21A2 mutations display clinical findings and metabolic/hormonal profile analogous to women with non classical congenital adrenal hyperplasia and polycystic ovary syndrome

Livadas Sarantis , Goulis Dimitrios , eBelardinelli Elisabetta , Armeni Elena , Solmi Beatrice , Veneti Stavroula , Lambrinoudaki Irene , Cecchetti Carolina , Macut Djuro P. , Gambineri Alessandra

Heterozygotes carrying CYP21A2 gene mutations are found in 5-10% of the general population in Mediterranean countries. Accumulating data suggest a survival advantage of this population, despite the fact that carriers of two mutations suffer from either classical or non-classical congenital adrenal hyperplasia (NC-CAH), an entity with increased mortality. In an attempt to elaborate on this issue we evaluated females of reproductive age with CYP21A2 heterozygocity (HET). We have...

ea0090rc4.6 | Rapid Communications 4: Reproductive and Developmental Endocrinology | ECE2023

Bone and sexual health in adult women with complete androgen insensivity syndrome: A single centre experience

Profka Eriselda , Rodari Giulia , Giacchetti Federico , Giavoli Claudia , Arosio Maura , Mantovani Giovanna

Background: Low bone mineral density (BMD) and reduced sexual satisfaction have been reported in complete androgen insensitivity syndrome (CAIS). Nevertheless, conclusive data on the prevalence and on the optimal management of these conditions are still lacking.Aims: To assess bone and sexual health in adult women with CAIS with and without gonadectomy.Methods: Single-centre, prospective study of 27 adult CAIS (age 35.2±8.7 ye...